Weekly Investment Analysts’ Ratings Changes for STAAR Surgical (STAA)

STAAR Surgical (NASDAQ: STAA) recently received a number of ratings updates from brokerages and research firms:

• 5/29/2026 – STAAR Surgical had its “outperform” rating reaffirmed by Wedbush. They now have a $40.00 price target on the stock.
• 5/16/2026 – STAAR Surgical was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/15/2026 – STAAR Surgical had its price target raised by Wells Fargo & Company from $16.00 to $25.00. They now have an “equal weight” rating on the stock.
• 5/14/2026 – STAAR Surgical had its price target raised by Canaccord Genuity Group Inc. from $27.00 to $32.00. They now have a “buy” rating on the stock.
• 5/14/2026 – STAAR Surgical had its price target raised by Piper Sandler from $16.00 to $33.00. They now have a “neutral” rating on the stock.
• 5/14/2026 – STAAR Surgical had its price target raised by Stifel Nicolaus from $18.00 to $31.00. They now have a “hold” rating on the stock.
• 5/14/2026 – STAAR Surgical was upgraded by Wedbush from “neutral” to “outperform”. They now have a $40.00 price target on the stock, up from $26.00.
• 5/14/2026 – STAAR Surgical had its price target raised by Mizuho from $22.00 to $27.00. They now have a “neutral” rating on the stock.
• 4/22/2026 – STAAR Surgical was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 4/11/2026 – STAAR Surgical was upgraded by Wall Street Zen to “hold”.
• 4/9/2026 – STAAR Surgical had its price target raised by Wedbush from $21.00 to $26.00. They now have a “neutral” rating on the stock.
• 4/9/2026 – STAAR Surgical was upgraded by Canaccord Genuity Group Inc. from “hold” to “buy”. They now have a $27.00 price target on the stock, up from $22.00.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, Director Broadwood Partners, L.P. bought 316,017 shares of STAAR Surgical stock in a transaction dated Friday, March 13th. The stock was acquired at an average cost of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the acquisition, the director owned 16,123,842 shares of the company’s stock, valued at approximately $300,064,699.62. This represents a 2.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought 670,213 shares of company stock valued at $12,266,249 over the last three months. 39.90% of the stock is currently owned by corporate insiders.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.